WAVEMAN · COMPANY

CVRX · Cvrx, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

CVRX

Name: CVRx, Inc. (CVRX) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

CVRx, Inc.

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001235912

ACTIVIST 13DC-SUITE BUYING · 1☆ WATCH

INSIDER NET · 180D

$73.1K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+10.4%

XBRL, annual

NET MARGIN

-94.1%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$73.1K over 180 days

+$73.1K over 90 days

more than 77% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

45 funds added or opened last quarter

below 63% of Medical Devices

REVENUE

+10.4% year over year

more than 57% of Medical Devices

MARGIN

-94.1% net margin

below 82% of Medical Devices

BUYBACKS

no share repurchases reported

SHORT

7.5% of shares outstanding short · 7.9 days to cover · settled 2026-07-31

more than 79% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

45 funds added or opened positions in the latest 13F quarter, of 90 holders.

Chernett Jorey disclosed a 5%+ stake (5.5%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -60.5%

-60.5%12M

INSIDER BUYINSIDER SELL13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

An activist crossed the 5% line with declared intent.

The record shows a net $73.1K bought by insiders over 180 days, 45 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, CVRx, Inc. insiders bought a net $73.1K of stock across 62 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Binkowski Brent

CHIEF OPERATING OFFICER

BUY

2026-08-13

26,223.0

$76.4K

Binkowski Brent

CHIEF OPERATING OFFICER

SELL

2026-08-12

1,309.0

$3.3K

Adamson Philip B.

Chief Medical Officer

SELL

2026-03-02

1,262.0

$10.0K

Hykes Kevin

PRES & CEO

SELL

2026-03-02

7,763.0

$61.3K

VERRASTRO PAUL

CHIEF MKTG & STRAT OFFICER

SELL

2026-03-02

1,284.0

$10.1K

62 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 57 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

JOHNSON & JOHNSON

4,024,861.0 sh

$20.7M

NEA Management Company, LLC

1,954,440.0 sh

$10.0M

BlackRock, Inc.

1,245,459.0 sh

$6.4M

ROYAL BANK OF CANADA

1,233,212.0 sh

$6.3M

GSK plc

1,007,583.0 sh

$5.2M

5%+ owners

13D = intent to influence · 13G = passive

Chernett Jorey

ACTIVIST 13D · 2026-08-24

5.5%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Ultra-Small Company Market Fund

$469.2K POSITION · AS OF 2026-03-31

0.4%

Goldman Sachs Small Cap Growth Insights Fund

$135.2K POSITION · AS OF 2026-04-30

0.0%

GuideMark Small/Mid Cap Core Fund

$40.2K POSITION · AS OF 2026-03-31

0.0%

iShares Micro-Cap ETF

$379.0K POSITION · AS OF 2026-03-31

0.0%

Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund

$51.9K POSITION · AS OF 2026-03-31

0.0%

Small Cap Core Fund

$63.8K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 10 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$56.7M	$51.3M	$39.3M	$22.5M
GROSS PROFIT	$48.3M	$43.0M	$33.0M	$17.5M
OPERATING INCOME	$-51.3M	$-59.5M	$-43.1M	$-42.5M
NET INCOME	$-53.3M	$-60.0M	$-41.2M	$-41.4M
EPS (DILUTED)	-2.04	-2.65	-1.99	-2.02
OPERATING CASH FLOW	$-40.2M	$-39.1M	$-39.0M	$-42.7M
CASH	$75.7M	$105.9M	$90.6M	$106.2M
LONG-TERM DEBT	$49.5M	$49.3M	$29.2M	$6.7M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE